OTCMKTS:ASCLF Ascletis Pharma (ASCLF) Stock Price, News & Analysis $0.63 0.00 (0.00%) As of 11/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Ascletis Pharma Stock (OTCMKTS:ASCLF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ascletis Pharma alerts:Sign Up Key Stats Today's Range$0.63▼$0.6350-Day Range$0.63▼$1.3052-Week Range$0.62▼$2.50VolumeN/AAverage Volume2,773 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ascletis Pharma Inc. is a China-based biopharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s research and development activities have centered on viral diseases, liver diseases, oncology and metabolic disorders, with an emphasis on therapies addressing significant unmet medical needs. Ascletis has developed and commercialized treatments for hepatitis C, including danoprevir, marketed in China under the brand name Ganovo. The company has also advanced additional antiviral programs and drug candidates targeting infectious diseases, while expanding its pipeline into areas such as cancer and metabolic disease. Founded in 2014 and headquartered in Hangzhou, China, Ascletis operates primarily in the Chinese pharmaceutical market and has pursued international development and collaboration opportunities. The company was founded and is led by Dr. Jinzi J. Wang, who serves as chairman and chief executive officer.AI Generated. May Contain Errors. Read More Receive ASCLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascletis Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASCLF Stock News HeadlinesAscletis Pharma Inc. (OTCMKTS:ASCLF) Sees Significant Decline in Short InterestNovember 17 at 5:40 AM | americanbankingnews.comAscletis Pharma (OTCMKTS:ASCLF) Shares Down 13.2% - Should You Sell?November 11, 2026 | americanbankingnews.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years. | Profits Run (Ad)Ascletis Grants 1.8 Million Share Options to EmployeesNovember 4, 2026 | tipranks.comAscletis Submits FDA IND for New Oral Amylin Agonist to Treat ObesityOctober 25, 2026 | tipranks.comAscletis Reports Preclinical Data For Oral Obesity Candidate ASC36oOctober 20, 2026 | rttnews.comAscletis Pharma Inc. gibt positive Ergebnisse einer 28-tägigen Proof-of-Concept-Studie in den USA zu ASC50 zur Behandlung von Plaque-Psoriasis bekanntSeptember 30, 2026 | de.marketscreener.comDAscletis' ASC50 Shows 48.9% PASI Reduction In Phase 1 Psoriasis TrialSeptember 29, 2026 | rttnews.comSee More Headlines ASCLF Stock Analysis - Frequently Asked Questions How have ASCLF shares performed this year? Ascletis Pharma's stock was trading at $1.4850 at the beginning of 2026. Since then, ASCLF shares have decreased by 57.9% and is now trading at $0.6250. How do I buy shares of Ascletis Pharma? Shares of ASCLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:ASCLF CIKN/A Webwww.ascletis.com Phone86-571-8538-9730FaxN/AEmployees202Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:ASCLF) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour secret “Black Friday” link for tradersMarkham Trading's complete Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 f...TradeWins | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascletis Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascletis Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.